Condition: Solid Tumors Harboring a TP53 Y220C Mutation · Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GenSci128 Tablet in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation
This description comes directly from the study's public registry record.
Wen Xu · +8618861095711 · xuwen01@genscigroup.com
Always discuss trial participation with your own doctor first.
| Zhongshan Hospital ,Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06908434